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Purpose: Benign tumors that arise from the meninges can be difficult to treat due to their
potentially large size and proximity to critical structures such as cranial nerves and sinuses.
Single fraction radiosurgery may increase the risk of symptomatic peritumoral edema. In
this study, we report our results on the efficacy and safety of five fraction image-guided
radiosurgery for benign meningiomas.
Materials/Methods: Clinical and radiographic data from 38 patients treated with five
fraction radiosurgery were reviewed retrospectively. Mean tumor volume was 3.83 mm3
(range, 1.08–20.79 mm3). Radiation was delivered using the CyberKnife, a frameless robotic
image-guided radiosurgery system with a median total dose of 25 Gy (range, 25–35 Gy).
Results: The median follow-up was 20 months. Acute toxicity was minimal with eight
patients (21%) requiring a short course of steroids for headache at the end of treat-
ment. Pre-treatment neurological symptoms were present in 24 patients (63.2%). Post
treatment, neurological symptoms resolved completely in 14 patients (58.3%), and were
persistent in eight patients (33.3%). There were no local failures, 24 tumors remained
stable (64%) and 14 regressed (36%). Pre-treatment peritumoral edema was observed in
five patients (13.2%). Post-treatment asymptomatic peritumoral edema developed in five
additional patients (13.2%). On multivariate analysis, pre-treatment peritumoral edema and
location adjacent to a large vein were significant risk factors for radiographic post-treatment
edema (p=0.001 and p=0.026 respectively).
Conclusion: These results suggest that five fraction image-guided radiosurgery is well
tolerated with a response rate for neurologic symptoms that is similar to other standard
treatment options. Rates of peritumoral edema and new cranial nerve deficits following
five fraction radiosurgery were low. Longer follow-up is required to validate the safety and
long-term effectiveness of this treatment approach.
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BACKGROUND
Meningiomas are commonly benign tumors with a generally favor-
able prognosis (1). However, without treatment they may progress
locally, compressing adjacent structures and causing neurologic
deficits. They pose a unique clinical challenge due to their large
size and variable anatomical locations within the skull (1). Surgical
resection of the entire tumor, when possible without neurologic
injury, is the standard of care with a 10-year local control of 80% or
higher (2–9). For subtotally resected or recurrent tumors, conven-
tionally fractionated radiation therapy (1.8–2.0 Gy per fraction)
to approximately 54 Gy improves local control (2, 4, 6–8).
More recent experience suggests a role for single fraction stereo-
tactic radiosurgery (SRS) (12–18 Gy) as a primary treatment for
well selected, small meningiomas or as adjuvant treatment for
residual disease (10–12). In cases where single fraction SRS has
been appropriately utilized, results have been excellent, demon-
strating equivalent local control to both conventional radiation
therapy and surgical resection for select groups of meningioma
patients (10, 11). Patients with large tumors (>7.5 cc) have a poor
prognosis with this approach, and unacceptably high rates of local
failure (10, 11).
Single fraction radiosurgery, however, may increase the risk
of symptomatic peritumoral edema and/or cranial nerve injury
(10, 12, 13). This risk of peritumoral edema may be increased in
tumors that are large, recurrent, adjacent to large veins, and/or
basally located (10, 13–19). Conventional fractionated radiation
therapy has been employed to treat these patients. The gross tumor
volume (GTV) is typically targeted with a margin of 2–5 mm to
adjust for set-up inaccuracy. Due to these large planned treatment
volumes (PTVs), treatment is generally fractionated over 25–30
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sessions to limit toxicity to adjacent normal structures. Due to the
long natural history of this disease, it is essential to maximize post-
treatment quality of life by preventing treatment related adverse
outcomes while minimizing neurological symptoms associated
with tumor progression. It is possible that some of the adverse
effects of single fraction radiosurgery for large tumors may be
mitigated by limited fractionation.
The CyberKnife is an image-guided, frameless, SRS platform.
The frameless configuration allows for staged treatment, and it
has been successfully utilized to treat a wide variety of intracra-
nial tumors including meningiomas (8, 9, 20). In this retrospec-
tive study, we report our preliminary results with five fraction
image-guided radiosurgery as a treatment for meningiomas, either
as monotherapy or as an adjuvant to surgical resection. This
treatment was conducted with the belief that its accurate and
highly conformal delivery would minimize peritumoral edema
and cranial nerve toxicity.
MATERIALS AND METHODS
PATIENT SELECTION AND TREATMENT
We performed a retrospective review of patients with benign
meningiomas treated with CyberKnife SRS from December 1st,
2007 to February 1st, 2011 by SPC and BTC. Patients who had
undergone SRS for intracranial meningiomas with or without
surgical resection were included in the present study. Patients with
atypical or malignant meningiomas were excluded from this study.
All patients were treated by an interdisciplinary team of radiation
oncologists and neurosurgeons. High resolution CT images were
obtained from all patients for pre-treatment planning with tar-
get volumes, and critical structures were manually delineated by
the treating neurosurgeon (Figure 1). The treating isodose and
prescription dose were determined by the treating radiation oncol-
ogist in consultation with the treating neurosurgeon, and took into
account the target volume, proximity to critical structures, and
previous treatment history. In most cases, the dose was prescribed
to the isodose surface that encompassed the margin of the tumor.
Treatment plans were generated using an inverse planning method
by the CyberKnife treatment software (Multiplan, Accuray).
FIGURE 1 | Fifty-three-year-old man with a right Meckel cave
meningioma. He presented with right facial pain. The decision was to
proceed with radiosurgery. Treatment planning axial (A) and sagittal (B)
computed tomography images demonstrating the GTV (red), brainstem
(blue), and chiasm (yellow). Isodose lines shown as follows: blue 79%
(prescription) and purple 50%. Note proximity of the meningioma to the
brainstem. The tumor was treated with 2500 cGy in five fractions and his
pain resolved.
OUTCOMES ASSESSMENT
Patients were tracked as part of routine clinical follow-up by the
interdisciplinary team. MRI scans were obtained at pre-defined
intervals, every 6 months for the first year, and then yearly there-
after, unless acute changes in neurological status warranted imme-
diate imaging. Neurological symptoms were clinically assessed and
recorded by the treating neurosurgeons. Peritumoral edema was
assessed on T2 weighted and FLAIR MRI sequences. Patient steroid
requirements were assessed at each clinical follow-up visit.
STATISTICAL ANALYSIS
All statistical analyses were performed utilizing SPSS Statistics
v19 (IBM). Statistical analysis was performed in order to iden-
tify pre-treatment and treatment variables that correlated with
post-treatment peritumoral edema. Due to the relatively small
sample size, Fisher’s Exact Test was used for categorical variables,
while Spearman’s Rho was employed for examining the interaction
between continuous variables and post-treatment peritumoral
edema. For analysis of volume and dose, due to the small sample
sizes, patients were stratified as being over or under the median
and a Chi-square test was employed. Alpha was set to 0.05 to yield
a 95% confidence interval (CI) for all statistical tests.
RESULTS
PATIENT AND TREATMENT CHARACTERISTICS
Thirty-eight patients were identified as having undergone treat-
ment for intracranial meningiomas and were subsequently
included in the current study (Table 1). Twenty-nine (79%) of
the patients were female and nine (24%) were male. The median
age at time of treatment with radiosurgery was 64 years. Thirteen
(34%) patients had undergone prior surgery, of which five were
classified as gross total resection and eight were classified as subto-
tal resections. The remaining 24 patients had received no previous
surgical or non-surgical interventions and were treated without
pathologic confirmation. Twenty-seven (71%) of the tumors were
primary, while 11 (29%) were recurrent. The tumors occurred
Table 1 | A summary of patient characteristics for patients included in
the study.
Characteristic N =38 (%)
Race/ethnicity
Caucasian 24 (63)
African American 11 (29)
Hispanic 1 (3)
Asian 2 (5)
Gender
Female 29 (76)
Male 9 (24)
Age at radiosurgery
Mean 62
Median 64
Extent of resection
Gross total 5 (13)
Subtotal 8 (21)
No surgery 24 (63)
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Table 2 | A summary of tumor characteristics for all tumors included
within the study.
Characteristic N =38 (%)
Primary vs. recurrent
Primary 27 (71)
Recurrent 11 (29)
Location: general
Basal 22 (58)
Non-basal 16 (42)
Location: specific
Bifrontal 1 (3)
Cavernous sinus 7 (18)
Cerebellopontine angle 5 (13)
Falcine 2 (5)
Falcotentorial 1 (3)
Lateral ventricle 1 (3)
Meckel’s cave 2 (5)
Middle cranial fossa 1 (3)
Parafalcine 2 (5)
Parasagittal 5 (13)
Parietal convexity 1 (3)
Parietal lobe 1 (3)
Petroclival 2 (5)
Posterior fossa 1 (3)
Sphenoid wing 2 (5)
Suprasellar 1 (3)
Temporal lobe 3 (8)
Volume (cc)
Min 1.08
Max 20.79
Mean 6.22
Median 3.84
at a variety of intracranial sites (Table 2), with an almost even
number of basal and non-basal tumors, 22 (58%) and 16 (42%)
respectively. The median tumor volume was 3.83 mm3 (range,
1.08–20.79 mm3). The median isodose was 82% (70–90%) which
was treated with a median prescription dose of 2500 cGy (2500–
3500 cGy) and resulted in a median percent tumor coverage of
99.5% (Table 3).
COMPLICATIONS AND NEUROLOGICAL SYMPTOMS AFTER SRS
Acute toxicity after SRS treatment included symptoms such as
headaches, fatigue, and nausea. Headaches were the most com-
mon complication with nine patients (23.7%) complaining of
headaches at the end of treatment. Four patients (10.5%) experi-
enced fatigue, and only one patient (2.6%) complained of nausea.
Twenty-four patients (63.2%) presented with neurological symp-
toms prior to therapy (Table 4). These neurological symptoms
included facial pain, hearing loss, diplopia, proptosis, vertigo,
facial numbness, and reduced visual acuity. After SRS, neurological
examination revealed complete resolution of neurological symp-
toms in 14 patients (58.3%), continued symptoms in eight patients
(33.3%), and recurrence of symptoms after initial improvement
in two patients (8.3%). Only one patient (2.6%) developed a
Table 3 | A summary of treatment characteristics for patients treated
on a frameless stereotactic radiosurgical system.
Characteristic N =38 Characteristic N =38
Rx dose (cGy) Percent tumor covered
Min 2500 Min 97.4
Max 3500 Max 99.9
Mean 2691 Mean 99.3
Median 2500 Median 99.5
Isodose line (%) Non-zero beams
Min 70 Min 88
Max 90 Max 259
Mean 82 Mean 175
Median 82 Median 174
Homogeneity index Collimator (mm)
Min 1 Min 5
Max 1.39 Max 15
Mean 1.22 Mean 11
Median 1.2 Median 10
New conformality index
Min 1.32
Max 2.25
Mean 1.66
Median 1.61
Table 4 | A summary of changes in neurological deficits.
Deficit Pre-
SRS
Improved
post-
SRS
Recurrence
after initial
improvement
Continued
Sx
post-SRS
Facial pain 9 5 2 2
Hearing loss 1 0 0 1
Diplopia 4 4 0 0
Proptosis 2 0 0 2
Vertigo 2 2 0 0
Facial numbness 4 3 0 1
Reduced visual acuity 2 0 0 2
All neurological deficits were noted by the treatment team on either clinical exam
or through direct questioning of the patient.
new deficit, facial numbness, immediately after radiation, which
resolved after a few days. Otherwise, no new neurological deficits
were observed after SRS.
Facial pain was the most common presenting neurological
symptom pre-SRS treatment. Of the nine patients (37.5%) who
presented with facial pain, five patients (55.6%) were asympto-
matic after radiation, two patients (22.2%) had continued symp-
toms, and another two patients (22.2%) had recurrent facial pain
after initial improvement. Diplopia, vertigo, and facial numbness
improved in the majority of patients. Proptosis and reduced visual
acuity did not improve with treatment.
LOCAL CONTROL RATE AND PERITUMORAL EDEMA
Twenty-four patients (63.2%) who underwent SRS showed no
change in tumor size, while 14 patients (36.8%) showed a decrease
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Table 5 | (A) A comprehensive table detailing individual patient outcomes with regards to pre-treatment therapies, radiation dosage, and
subsequent clinical outcomes. (B) A summary of individual patient factors and whether patients had pre-treatment or post-treatment
peritumoral edema.
(A)
Patient Location treated Surgery Cumulative
dose
Local outcome Acute toxicity Post-radiation
steroids
1 Temporal lobe None 3000 Decreased Headache Yes
2 Tentorial None 3500 Decreased No No
3 Posterior Temporal lobe Subtotal 3000 Stable No No
4 Cavernous sinus Subtotal 2500 Decreased No No
5 CPA None 2750 Stable No No
6 CPA None 2750 Stable No No
7 Cavernous sinus None 2500 Stable No No
8 Cavernous sinus None 2500 Stable Headache Yes
9 Parasagittal Gross total 2500 Stable Fatigue No
10 Parietal falcine Subtotal 2500 Stable No No
11 Parietal Parasagittal Gross total 2500 Stable Headache No
12 Petroclival Subtotal 2500 Stable Fatigue No
13 Medial sphenoid wing Subtotal 2500 Stable Fatigue and headache No
14 Middle cranial fossa None 3000 Stable Headache Yes
15 Petroclival None 2500 Stable Headache Yes
16 Cavernous sinus Subtotal 2500 Decreased No No
17 Frontal parafalcine None 2500 Decreased No No
18 Sphenoid wing None 2500 Decreased No No
19 CPA None 2500 Stable No No
20 Parietal convexity None 2500 Stable No No
21 CPA None 2500 Stable No Yes
22 Anterior parafalcine None 3000 Decreased Headache and nausea Yes
23 Bifrontal None 3000 Stable No No
24 CPA None 3000 Decreased Headache No
25 Anterior falcine Gross total 3000 Decreased No No
26 Cavernous sinus None 2500 Decreased No No
27 Falcotentorial Subtotal 2500 Stable No No
28 Posterior fossa Subtotal 3000 Stable No No
29 Posterior Parasagittal Gross total 2500 Stable No No
30 Cavernous sinus None 2500 Stable No No
31 Parafalcine None 2500 Decreased No No
32 Anterior temporal Gross total 3000 Decreased Headache Yes
33 Lateral ventricle None 3000 Stable No No
34 Suprasellar None 2500 Stable Fatigue Yes
35 Cavernous sinus None 2500 Decreased Hypesthesia No
36 Meckel’s cave None 2500 Stable No No
37 Meckel’s cave None 2750 Decreased No No
38 Parietal lobe Gross total 3000 Stable No No
(B)
Patient Anatomical
classification
Volume (cc) Recurrence Adjacent
to vein
Pre-treatment
peritumoral edema
Post-treatment
peritumoral edema
1 Non-basal 1.08 No No No No
2 Non-basal 1.6 No Yes No Yes
3 Non-basal 16.7 Yes No Yes Yes
4 Basal 5.56 Yes Yes Yes Yes
5 Basal 1.37 No No No No
6 Basal 2.56 No Yes No No
(Continued)
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Table 5 | Continued
Patient Anatomical
classification
Volume (cc) Recurrence Adjacent
to vein
Pre-treatment
peritumoral edema
Post-treatment
peritumoral edema
7 Basal 4.05 No No No No
8 Basal 12.19 No No No No
9 Non-basal 11.24 Yes No Yes Yes
10 Non-basal 6.48 Yes No No No
11 Non-basal 6.44 Yes Yes No No
12 Basal 2.12 Yes No No No
13 Basal 20.17 No No No No
14 Basal 2.14 No Yes No Yes
15 Basal 20.79 No No No No
16 Basal 13.82 No Yes Yes Yes
17 Non-basal 6.43 No No No No
18 Basal 5.48 No No No No
19 Basal 10.84 No No No No
20 Non-basal 3.24 No No No No
21 Basal 12.13 No No No Yes
22 Non-basal 1.17 No No No No
23 Non-basal 6.59 No No No No
24 Basal 1.53 No No No No
25 Non-basal 3.59 Yes Yes Yes Yes
26 Basal 13.07 No No No No
27 Non-basal 4.68 No No No No
28 Basal 11.83 Yes No No No
29 Non-basal 2.63 Yes No No Yes
30 Basal 2.65 No No No No
31 Non-basal 2.611 No No No Yes
32 Non-basal 3.04 Yes Yes No No
33 Non-basal 3.628 No Yes No No
34 Basal 2.62 No No No No
35 Basal 1.38 No Yes No No
36 Basal 4.97 No No No No
37 Basal 1.90 No Yes No No
38 Non-basal 1.89 Yes Yes No No
Table 6 | A statistical analysis of variables associated with peritumoral
edema.
Pre-treatment characteristic Likelihood ratio p-Value
Pre-treatment peritumoral edema 15.77 0.001
Anatomical classification 1.28 0.293
Adjacent to vein 4.83 0.045
Volume (cc) 0 1
Recurrence 2.77 0.116
Cumulative dose 0.002 0.968
p-Values are for two-sided Fisher’s Exact Test.
in tumor size resulting in a crude radiographic local control rate
of 100% of the meningiomas treated with SRS (Table 5).
Intracranial edema is commonly managed with oral steroids,
and oral steroid requirements were measured as a surro-
gate for post-radiation peritumoral edema. Symptomatic, acute,
post-radiation edema requiring steroids occurred in six patients
(15.8%). In addition, two patients (5.3%) were given steroids due
to evidence of post-radiation edema on MRI, but without any
clinical signs of toxicity (Table 5).
Pre-SRS radiographic peritumoral edema continued to be
observed in five patients (13.2%) on follow-up MRI imaging.
Of these patients, four (10.5%) had recurrent tumors following
a subtotal or gross resection, and three (7.9%) had a radio-
logical tumor volume greater than 10.0 cc (Table 5). A total of
10 patients had post-treatment radiographic peritumoral edema,
with new onset being observed in five patients (13.2%). On uni-
variate statistical analysis, only pre-treatment peritumoral edema
(p= 0.001) and adjacency to a large vein (p= 0.045) correlated
with post-treatment peritumoral edema (Table 6).
DISCUSSION
Our results show that fractionated SRS may provide similar
local control with minimal toxicity and excellent quality of
life. Headaches, fatigue, and nausea were the only three acute
complaints, all of which resolved over time. Headaches were the
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most common complication, present in 23.7% of our patients,
which is consistent with other studies (12). Nausea was the least
common, present in only one patient. This trend has also been
observed in previous studies (21, 22).
In this study several patients presented with neurological symp-
toms and the majority responded to treatment with minimal
toxicity at 2 years of follow-up. The present response rate of neu-
rological symptoms compares favorably to similar studies with
Gamma Knife (17, 21). Kondziolka et al. noted that five patients
in their series of 99 cases had new or worsened deficits occurring
3–31 months after radiosurgery, while Chang et al. reported two
cases out of 140 experiencing worsened deficits. Most tellingly,
Kondziolka et al. reported that 67 out of 70 patients reported that
their treatments were subjectively “successful” on an outcomes
questionnaire, indicative of a high preservation of quality of life
post-SRS (21). Uniquely, we have found an excellent response of
tumor-associated facial pain to five fraction radiosurgery. While
documented in other studies involving single fraction radio-
surgery, our results suggest that a five fraction approach can also
yield a beneficial reduction in tumor-associated trigeminal neu-
ralgia (23–25). Other studies have suggested that recurrence of
these symptoms typically occurs within 2 years, and is more likely
to recur for malignant skull base tumors, with the mechanism of
relief being decompression of affected nerve roots (24, 25).
Stereotactic radiosurgery was well tolerated with few post-
treatment complications. As previously mentioned, other studies
have suggested a relationship between tumor volume and post-SRS
edema and complications (26). However, we found no correlation
found between tumor volume, margin dose, and the presence of
complications, which is similar to findings in other studies (12,
14, 22). Furthermore, it may be that if such a relationship does
exist between large tumor volume and complications, that it may
be mitigated in part through dose fractionation like in the present
study.
At roughly 2 years, none of the patients developed local failures,
and 14 showed a decrease in tumor size that may be correlated
favorably with local control, although this has not been conclu-
sively shown (27). There is a high degree of variability in volume
reduction post-radiosurgery with studies reporting rates less than
20% and over 60%, ultimately the implications and the time course
of post-radiosurgery volume reduction need to be further stud-
ied to ascertain its prognostic implications (21, 28). With regards
to local control, control rates for meningiomas post-radiosurgery
typically require longer follow-up for thorough assessment, with
many studies placing the 10-year rate of local control at 84% (11,
22, 29).
Only 13% of the patients developed new onset post-SRS
peritumoral edema, with 26% of patients developing it over-
all. In addition, only 2.6% of the patient group receiving
five fraction radiosurgery had symptomatic peritumoral edema.
These results are in agreement with other papers on the use
of hypofractionated radiosurgery for meningiomas, and com-
pares favorably to an average of 5–10% of patients devel-
oping symptomatic edema in other studies (12, 21, 30, 31).
In one such study by Kollova et al. edema was more com-
mon in tumor volumes greater than 10 cm3 (26). However the
present study and others have suggested that simple tumor vol-
ume is not a significant contributor to post-radiation peritu-
moral edema, which may be in fact more due to the inter-
face between meningioma and cortical tissue rather than gross
volume (21, 32).
CONCLUSION
Stereotactic radiosurgery is a safe and effective treatment for
benign intracranial meningiomas with or without surgical resec-
tion. Dose fractionation is well tolerated, and may offer equivalent
local control to single session SRS. Fractionation may offer par-
ticular benefit to patients with large tumors located in critical
locations or in other high-risk patients. Further studies are war-
ranted to fully ascertain the potential benefits and risks of dose
fractionation for SRS therapy of meningiomas, and its ultimate
impact on local control.
REFERENCES
1. Alexiou GA, Gogou P, Markoula
S, Kyritsis AP. Management of
meningiomas. Clin Neurol Neu-
rosurg (2010) 112:177–82. doi:10.
1016/j.clineuro.2009.12.011
2. Simpson D. The recurrence of
intracranial meningiomas after sur-
gical treatment. J Neurol Neurosurg
Psychiatry (1957) 20:22–39. doi:10.
1136/jnnp.20.1.22
3. Mirimanoff RO, Dosoretz DE, Ling-
good RM, Ojemann RG, Martuza
RL. Meningioma: analysis of recur-
rence and progression following
neurosurgical resection. J Neuro-
surg (1985) 62:18–24. doi:10.3171/
jns.1985.62.1.0018
4. Barbaro NM, Gutin PH, Wilson CB,
Sheline GE, Boldrey EB, Wara WM.
Radiation therapy in the treatment
of partially resected meningiomas.
Neurosurgery (1987) 20:525–8.
doi:10.1227/00006123-198704000-
00003
5. Condra KS, Buatti JM, Menden-
hall WM, Friedman WA, Mar-
cus RB Jr, Rhoton AL. Benign
meningiomas: primary treatment
selection affects survival. Int J
Radiat Oncol Biol Phys (1997)
39:427–36. doi:10.1016/S0360-
3016(97)00317-9
6. Soyuer S, Chang EL, Selek U, Shi
W, Maor MH, Demonte F. Radio-
therapy after surgery for benign
cerebral meningioma. Radiother
Oncol (2004) 71:85–90. doi:10.
1016/j.radonc.2004.01.006
7. Rogers L, Mehta M. Role of radi-
ation therapy in treating intracra-
nial meningiomas. Neurosurg Focus
(2007) 23:E4. doi:10.3171/FOC-07/
10/E4
8. Colombo F, Casentini L,
Cavedon C, Scalchi P, Cora S,
Francescon P. Cyberknife radio-
surgery for benign meningiomas:
short-term results in 199 patients.
Neurosurgery (2009) 64:A7–13.
doi:10.1227/01.NEU.0000338947.
84636.A6
9. Coppa ND, Raper DM, Zhang Y,
Collins BT, Harter KW, Gagnon
GJ, et al. Treatment of malig-
nant tumors of the skull base with
multi-session radiosurgery. J Hema-
tol Oncol (2009) 2:16. doi:10.1186/
1756-8722-2-16
10. Kondziolka D, Flickinger JC,
Perez B. Judicious resection
and/or radiosurgery for parasagit-
tal meningiomas: outcomes
from a multicenter review.
Gamma Knife Meningioma
Study Group. Neurosurgery (1998)
43:405–13; discussion 413–4.
doi:10.1097/00006123-199809000-
00001
11. Pollock BE, Stafford SL, Utter
A, Giannini C, Schreiner SA.
Stereotactic radiosurgery pro-
vides equivalent tumor control
to Simpson Grade 1 resection for
patients with small- to medium-size
meningiomas. Int J Radiat Oncol
Biol Phys (2003) 55:1000–5. doi:10.
1016/S0360-3016(02)04356-0
12. DiBiase SJ, Kwok Y, Yovino S,
Arena C, Naqvi S, Temple R, et
al. Factors predicting local tumor
control after gamma knife stereo-
tactic radiosurgery for benign
intracranial meningiomas. Int J
Radiat Oncol Biol Phys (2004)
60:1515–9. doi:10.1016/j.ijrobp.
2004.05.073
13. Ganz JC, Schrottner O, Pendl
G. Radiation-induced edema after
Gamma Knife treatment for menin-
giomas. Stereotact Funct Neurosurg
(1996) 66(Suppl 1):129–33. doi:10.
1159/000099778
14. Nakamura S, Hiyama H, Arai K,
Nakaya K, Sato H, Hayashi M,
et al. Gamma Knife radiosurgery
for meningiomas: four cases of
radiation-induced edema.Stereotact
Funct Neurosurg (1996) 66(Suppl
1):142–5. doi:10.1159/000099804
Frontiers in Oncology | Radiation Oncology August 2013 | Volume 3 | Article 213 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oermann et al. Five fraction SRS for meningiomas
15. Vermeulen S, Young R, Li F, Meier
R, Raisis J, Klein S, et al. A com-
parison of single fraction radio-
surgery tumor control and toxicity
in the treatment of basal and non-
basal meningiomas. Stereotact Funct
Neurosurg (1999) 72(Suppl 1):
60–6.
16. Singh VP, Kansai S, Vaishya S,
Julka PK, Mehta VS. Early com-
plications following gamma knife
radiosurgery for intracranial
meningiomas. J Neurosurg (2000)
93(Suppl 3):57–61.
17. Chang JH, Chang JW, Choi JY,
Park YG, Chung SS. Complications
after gamma knife radiosurgery for
benign meningiomas. J Neurol Neu-
rosurg Psychiatry (2003) 74:226–30.
doi:10.1136/jnnp.74.2.226
18. Conti A, Pontoriero A, Salamone I,
Siragusa C, Midili F, La Torre D,
et al. Protecting venous structures
during radiosurgery for parasagit-
tal meningiomas. Neurosurg Focus
(2009) 27:E11. doi:10.3171/2009.8.
FOCUS09-157
19. Hasegawa T, Kida Y, Yoshimoto
M, Iizuka H, Ishii D, Yoshida K.
Gamma Knife surgery for con-
vexity, parasagittal, and falcine
meningiomas. J Neurosurg (2011)
114:1392–8. doi:10.3171/2010.11.
JNS10112
20. Oermann E, Collins BT, Erick-
son KT, Yu X, Lei S, Suy S, et
al. CyberKnife enhanced conven-
tionally fractionated chemoradia-
tion for high grade glioma in close
proximity to critical structures. J
Hematol Oncol (2010) 3:22. doi:10.
1186/1756-8722-3-22
21. Kondziolka D, Levy EI,
Niranjan A, Flickinger JC, Lunsford
LD. Long-term outcomes after
meningioma radiosurgery: physi-
cian and patient perspectives.
J Neurosurg (1999) 91:44–50.
doi:10.3171/jns.1999.91.1.0044
22. Stafford SL, Pollock BE, Foote RL,
Link MJ, Gorman DA, Schomberg
PJ, et al. Meningioma radiosurgery:
tumor control, outcomes, and
complications among 190 consecu-
tive patients. Neurosurgery (2001)
49:1029–37; discussion 1037–28.
doi:10.1097/00006123-200111000-
00001
23. Chang JW, Kim SH, Huh R, Park
YG, Chung SS. The effects of stereo-
tactic radiosurgery on secondary
facial pain. Stereotact Funct Neu-
rosurg (1999) 72(Suppl 1):29–37.
doi:10.1159/000056436
24. Pollock BE, Iuliano BA, Foote
RL, Gorman DA. Stereotactic
radiosurgery for tumor-related
trigeminal pain. Neurosurgery
(2000) 46:576–82; discussion
582–3. doi:10.1097/00006123-
200003000-00010
25. Squire SE, Chan MD, Furr RM,
Lowell DA, Tatter SB, Ellis TL,
et al. Gamma knife radiosurgery
in the treatment of tumor-related
facial pain. Stereotact Funct Neuro-
surg (2012) 90:145–50. doi:10.1159/
000335873
26. Kollova A, Liscak R, Novotny J Jr,
Vladyka V, Simonova G, Janouskova
L. Gamma Knife surgery for
benign meningioma. J Neurosurg
(2007) 107:325–36. doi:10.3171/
JNS-07/08/0325
27. Kondziolka D, Mathieu D, Lunsford
LD, Martin JJ, Madhok R, Niranjan
A, et al. Radiosurgery as definitive
management of intracranial menin-
giomas.Neurosurgery (2008) 62:53–
8; discussion 58–60. doi:10.1227/01.
NEU.0000311061.72626.0D
28. Minniti G, Amichetti M, Enrici
RM. Radiotherapy and radiosurgery
for benign skull base meningiomas.
Radiat Oncol (2009) 4:42. doi:10.
1186/1748-717X-4-42
29. Zada G, Pagnini PG, Yu C, Erick-
son KT, Hirschbein J, Zelman
V, et al. Long-term outcomes
and patterns of tumor progres-
sion after gamma knife radiosurgery
for benign meningiomas. Neuro-
surgery (2010) 67:322–8; discus-
sion 328–29. doi:10.1227/01.NEU.
0000371974.88873.15
30. Santacroce A, Walier M, Regis J,
Liscak R, Motti E, Lindquist C,
et al. Long-term tumor control of
benign intracranial meningiomas
after radiosurgery in a series of
4565 patients. Neurosurgery (2012)
70:32–9; discussion 39. doi:10.1227/
NEU.0b013e31822d408a
31. Unger KR, Lominska CE, Chanya-
sulkit J, Randolph-Jackson P, White
RL, Aulisi E, et al. Risk factors
for posttreatment edema in patients
treated with stereotactic radio-
surgery for meningiomas. Neuro-
surgery (2012) 70:639–45. doi:10.
1227/NEU.0b013e3182351ae7
32. Cai R, Barnett GH, Novak E,
Chao ST, Suh JH. Principal risk
of peritumoral edema after stereo-
tactic radiosurgery for intracra-
nial meningioma is tumor-brain
contact interface area. Neurosurgery
(2010) 66:513–22. doi:10.1227/01.
NEU.0000365366.53337.88
Conflict of Interest Statement: Brian
Timothy Collins and Sean P. Collins
have received honoraria from Accu-
ray Inc. The other co-authors declare
that the research was conducted in the
absence of any commercial or financial
relationships that could be construed as
a potential conflict of interest.
Received: 23 June 2013; paper pending
published: 17 July 2013; accepted: 03
August 2013; published online: 20 August
2013.
Citation: Oermann EK, Bhandari R,
Chen VJ, Lebec G, Gurka M, Lei S, Chen
L, Suy S, Azumi N, Berkowitz F, Kalhorn
C, McGrail K, Collins BT, Jean WC and
Collins SP (2013) Five fraction image-
guided radiosurgery for primary and
recurrent meningiomas. Front. Oncol.
3:213. doi: 10.3389/fonc.2013.00213
This article was submitted to Radiation
Oncology, a section of the journal Fron-
tiers in Oncology.
Copyright © 2013 Oermann, Bhandari,
Chen, Lebec, Gurka, Lei, Chen, Suy,
Azumi, Berkowitz, Kalhorn, McGrail,
Collins, Jean andCollins. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) or licensor
are credited and that the original publica-
tion in this journal is cited, in accordance
with accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.
www.frontiersin.org August 2013 | Volume 3 | Article 213 | 7
